Neuropace Net Income
| NPCE Stock | USD 15.49 0.60 3.73% |
As of the 6th of February, Neuropace secures the Mean Deviation of 3.1, downside deviation of 2.52, and Risk Adjusted Performance of 0.1161. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuropace, as well as the relationship between them. Please verify Neuropace value at risk, as well as the relationship between the semi variance and kurtosis to decide if Neuropace is priced some-what accurately, providing market reflects its recent price of 15.49 per share. Given that Neuropace has jensen alpha of 0.7131, we recommend you to check Neuropace's last-minute market performance to make sure the company can sustain itself at a future point.
Neuropace Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.7987 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -24.4 M | -25.6 M | |
| Net Loss | -42.4 M | -44.5 M | |
| Net Loss | -24.4 M | -25.6 M | |
| Net Loss | (0.84) | (0.88) |
Neuropace | Net Income | Build AI portfolio with Neuropace Stock |
Analyzing Neuropace's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Neuropace's current valuation and future prospects.
Latest Neuropace's Net Income Growth Pattern
Below is the plot of the Net Income of Neuropace over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Neuropace financial statement analysis. It represents the amount of money remaining after all of Neuropace operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Neuropace's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuropace's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (27.14 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Neuropace Net Income Regression Statistics
| Arithmetic Mean | (30,431,891) | |
| Coefficient Of Variation | (16.94) | |
| Mean Deviation | 2,920,274 | |
| Median | (29,973,000) | |
| Standard Deviation | 5,155,384 | |
| Sample Variance | 26.6T | |
| Range | 22.8M | |
| R-Value | 0.0003 | |
| Mean Square Error | 28.3T | |
| R-Squared | 0.0000001 | |
| Significance | 1.00 | |
| Slope | 320.44 | |
| Total Sum of Squares | 425.2T |
Neuropace Net Income History
Other Fundumenentals of Neuropace
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Neuropace Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Neuropace is extremely important. It helps to project a fair market value of Neuropace Stock properly, considering its historical fundamentals such as Net Income. Since Neuropace's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neuropace's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neuropace's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Neuropace 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neuropace's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neuropace.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Neuropace on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Neuropace or generate 0.0% return on investment in Neuropace over 90 days. Neuropace is related to or competes with Cerus, Rxsight, CVRx, 908 Devices, Brainsway, Senseonics Holdings, and Sight Sciences. NeuroPace, Inc. operates as a medical device company in the United States More
Neuropace Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neuropace's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neuropace upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.52 | |||
| Information Ratio | 0.135 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.34) | |||
| Potential Upside | 6.3 |
Neuropace Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuropace's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neuropace's standard deviation. In reality, there are many statistical measures that can use Neuropace historical prices to predict the future Neuropace's volatility.| Risk Adjusted Performance | 0.1161 | |||
| Jensen Alpha | 0.7131 | |||
| Total Risk Alpha | 0.5361 | |||
| Sortino Ratio | 0.3043 | |||
| Treynor Ratio | 0.3202 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neuropace's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neuropace February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1161 | |||
| Market Risk Adjusted Performance | 0.3302 | |||
| Mean Deviation | 3.1 | |||
| Semi Deviation | 2.04 | |||
| Downside Deviation | 2.52 | |||
| Coefficient Of Variation | 699.8 | |||
| Standard Deviation | 5.67 | |||
| Variance | 32.19 | |||
| Information Ratio | 0.135 | |||
| Jensen Alpha | 0.7131 | |||
| Total Risk Alpha | 0.5361 | |||
| Sortino Ratio | 0.3043 | |||
| Treynor Ratio | 0.3202 | |||
| Maximum Drawdown | 43.2 | |||
| Value At Risk | (4.34) | |||
| Potential Upside | 6.3 | |||
| Downside Variance | 6.33 | |||
| Semi Variance | 4.18 | |||
| Expected Short fall | (4.11) | |||
| Skewness | 4.63 | |||
| Kurtosis | 28.88 |
Neuropace Backtested Returns
Neuropace appears to be not too volatile, given 3 months investment horizon. Neuropace has Sharpe Ratio of 0.0875, which conveys that the firm had a 0.0875 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Neuropace, which you can use to evaluate the volatility of the firm. Please exercise Neuropace's Downside Deviation of 2.52, risk adjusted performance of 0.1161, and Mean Deviation of 3.1 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Neuropace holds a performance score of 6. The company secures a Beta (Market Risk) of 2.5, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuropace will likely underperform. Please check Neuropace's value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Neuropace's current price movements will revert.
Auto-correlation | 0.42 |
Average predictability
Neuropace has average predictability. Overlapping area represents the amount of predictability between Neuropace time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neuropace price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Neuropace price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.37 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Neuropace Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Neuropace reported net income of (27.14 Million). This is 107.95% lower than that of the Health Care Equipment & Supplies sector and 111.4% lower than that of the Health Care industry. The net income for all United States stocks is 104.75% higher than that of the company.
Neuropace Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuropace's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics of similar companies.Neuropace is currently under evaluation in net income category among its peers.
Neuropace ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neuropace's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neuropace's managers, analysts, and investors.Environmental | Governance | Social |
Neuropace Institutional Holders
Institutional Holdings refers to the ownership stake in Neuropace that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Neuropace's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neuropace's value.| Shares | Deerfield Management Co | 2025-06-30 | 500 K | Geode Capital Management, Llc | 2025-06-30 | 485.2 K | Lord, Abbett & Co Llc | 2025-06-30 | 400.7 K | State Street Corp | 2025-06-30 | 368.7 K | Silvercrest Asset Management Group Llc | 2025-06-30 | 298.7 K | Nantahala Capital Management, Llc | 2025-06-30 | 295.1 K | Divisadero Street Capital Management, Lp | 2025-06-30 | 242.1 K | Northern Trust Corp | 2025-06-30 | 232 K | Palumbo Wealth Management Llc | 2025-06-30 | 169.9 K | Orbimed Advisors, Llc | 2025-06-30 | 2.6 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.6 M |
Neuropace Fundamentals
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 541.09 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Shares Owned By Insiders | 2.71 % | ||||
| Shares Owned By Institutions | 92.60 % | ||||
| Number Of Shares Shorted | 893.69 K | ||||
| Price To Book | 29.10 X | ||||
| Price To Sales | 5.65 X | ||||
| Revenue | 79.91 M | ||||
| Gross Profit | 72.83 M | ||||
| EBITDA | (16.57 M) | ||||
| Net Income | (27.14 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 73.34 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (17.95 M) | ||||
| Short Ratio | 3.40 X | ||||
| Earnings Per Share | (0.75) X | ||||
| Target Price | 19.5 | ||||
| Number Of Employees | 209 | ||||
| Beta | 1.86 | ||||
| Market Capitalization | 535.92 M | ||||
| Total Asset | 94.65 M | ||||
| Retained Earnings | (530.95 M) | ||||
| Working Capital | 66.18 M | ||||
| Net Asset | 94.65 M |
About Neuropace Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.75) | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets | Return On Equity |
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value - what Neuropace's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.